AcuityMD Nears Unicorn Valuation With $80M Series C as AI MedTech Platform Expands

AcuityMD, a MedTech commercialization software provider, closed an $80 million Series C round this week, valuing the company at about $955 million and bringing total funding to more than $160 million. The round was led by StepStone Group with participation from existing backers Benchmark, Redpoint, ICONIQ, and Atreides Management, underscoring strong investor confidence.

The company reports that nearly 500 MedTech firms now use its platform, including 16 of the top 20 players, highlighting broad adoption across the sector. AcuityMD plans to deploy the new capital to advance “agentic AI” tools for commercial teams, deepen its data ontology, and extend its software beyond sales into the broader MedTech product lifecycle.

Management is emphasizing the integration of claims data, FDA filings, and government records to build defensible data assets and raise switching costs for clients. A recent case study at Kuros Biosciences showcased AcuityAI, where a sales leader generated an AI-driven business plan for a new national health system contract, compressing hours of research into a single automated workflow.

In parallel, AcuityMD is increasing its focus on the rapid shift of procedures into ambulatory surgery centers, particularly in orthopedics and cardiovascular care. Through its presence at the ASCA2026 conference and public commentary, the company is positioning its analytics to support site-of-care and case volume strategies in one of healthcare’s fastest-growing segments.

This dual emphasis on advanced AI capabilities and ASC-focused analytics could expand AcuityMD’s addressable market and deepen its role as infrastructure for MedTech commercialization and planning. Overall, the week marked a significant milestone for AcuityMD, combining fresh capital, strong customer traction, and strategic alignment with key industry trends.